CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $11.93B, above the global median of $1.18B
- PositionPrice-to-book is 22.78×, higher than 95% of its Biotechnology peers (median 2.86×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
11.93BUSDvs all stocks (USD)
Revenue (TTM)
1.28BUSDvs all stocks (USD)
Profit Margin
-25.32%vs Biotechnology peers
Beta
-0.9900xvs all stocks
52-Week Change
16.58%vs all stocks
Market Capitalization
11.93BUSDvs all stocks (USD)
Enterprise Value
11.44BUSDvs all stocks (USD)
Forward P/E
53.67xvs Biotechnology peers
Price to Sales (TTM)
9.30xvs Biotechnology peers
Price to Book (MRQ)
22.78xvs Biotechnology peers
Enterprise to Revenue
8.91xvs Biotechnology peers
Enterprise to EBITDA
-35.64xvs Biotechnology peers
Gross Margin
89.02%vs Biotechnology peers
Profit Margin
-25.32%vs Biotechnology peers
Operating Margin
-15.46%vs Biotechnology peers
Return on Assets (TTM)
-17.84%vs Biotechnology peers
Return on Equity (TTM)
-53.31%vs Biotechnology peers
Revenue (TTM)
1.28BUSDvs all stocks (USD)
Revenue per Share (TTM)
56.15USDUpdated Sep 28, 2026Quarterly Revenue Growth
71.20%vs Biotechnology peers
Gross Profit (TTM)
1.17BUSDvs all stocks (USD)
EBITDA (TTM)
-321.10MUSDvs all stocks (USD)
Net Income (TTM)
-325.10MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
71.17%vs Biotechnology peers
Operating Cash Flow (TTM)
-197.72MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-80.47MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
958.40MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
56.15MUSDFY2025 · Dec 31, 2025Gross Profit
902.25MUSDFY2025 · Dec 31, 2025Operating Income
-300.10MUSDvs all stocks (USD)
Pre-tax Income
-288.28MUSDFY2025 · Dec 31, 2025Net Income
-288.28MUSDFY2025 · Dec 31, 2025EBIT
-265.98MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-261.69MUSDFY2025 · Dec 31, 2025Research & Development
388.52MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
813.83MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
37.36MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
22.31MUSDFY2025 · Dec 31, 2025EPS (Basic)
-12.85USDFY2025 · Dec 31, 2025EPS (Diluted)
-12.85USDFY2025 · Dec 31, 2025Basic Shares Outstanding
22.43MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
22.43MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-288.28MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-296.19MUSDFY2025 · Dec 31, 2025Free Cash Flow
-296.65MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
203.78MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-288.28MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.51MUSDFY2025 · Dec 31, 2025Stock-based Compensation
98.13MUSDFY2025 · Dec 31, 2025Other Non-cash Items
4.81MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-80.65MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
5.28MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-36.98MUSDFY2025 · Dec 31, 2025Capital Expenditures
-467.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-3.00MUSDFY2025 · Dec 31, 2025Purchase of Investments
-1.05BUSDFY2025 · Dec 31, 2025Sale of Investments
1.08BUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
35.32MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
350.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-121.66MUSDFY2025 · Dec 31, 2025Other Financing Charges
-10.41MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
217.93MUSDFY2025 · Dec 31, 2025Shares Outstanding
23.09MSharesUpdated Sep 28, 2026Float Shares
13.72MSharesUpdated Sep 28, 2026Shares Short
2.25MSharesUpdated Sep 28, 2026Short Ratio
10.22daysvs all stocks
Short % of Shares Outstanding
11.47%vs all stocks
% Held by Insiders
5.83%vs all stocks
% Held by Institutions
104.47%vs all stocks
Total Cash (MRQ)
838.75MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
36.30USDUpdated Sep 28, 2026Total Debt (MRQ)
347.75MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.6640xvs Biotechnology peers
Current Ratio (MRQ)
3.21xvs Biotechnology peers
Book Value per Share (MRQ)
22.68USDUpdated Sep 28, 2026Total Assets
1.26BUSDvs all stocks (USD)
Total Current Assets
1.25BUSDFY2025 · Dec 31, 2025Total Liabilities
656.90MUSDFY2025 · Dec 31, 2025Total Non-current Assets
13.82MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
346.61MUSDFY2025 · Dec 31, 2025Total Current Liabilities
310.29MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
198.69MUSDFY2025 · Dec 31, 2025Other Short-term Investments
784.87MUSDFY2025 · Dec 31, 2025Accounts Receivable
134.48MUSDFY2025 · Dec 31, 2025Inventory
74.84MUSDFY2025 · Dec 31, 2025Accounts Payable
48.88MUSDFY2025 · Dec 31, 2025Short-term Debt
1.02MUSDFY2025 · Dec 31, 2025Long-term Debt
346.61MUSDFY2025 · Dec 31, 2025Common Stock (Book)
2.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-2.09BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
602.69MUSDvs all stocks (USD)
52-Week Low
393.61USDUpdated Sep 28, 202652-Week High
615.00USDUpdated Sep 28, 202652-Week Change
16.58%vs all stocks
Beta
-0.9900xvs all stocks
50-Day MA
527.00USDUpdated Sep 28, 2026200-Day MA
512.01USDUpdated Sep 28, 2026Avg 10-Day Volume
233.91KSharesUpdated Sep 28, 2026Avg 30-Day Volume
226.36KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-14.00USDUpdated Sep 28, 2026Other Income / Expense
-3.24MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 22.78×, higher than 95% of its Biotechnology peers (median 2.86×)Significant
Price-to-book: 22.78Industry median: 2.86Industry P95: 13.08Peers compared: 260
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.89Profit Margin: -0.25
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.57
Altman Z-Score 9.53: safe zoneNotable
Altman Z-Score: 9.53
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $11.93B, above the global median of $1.18BNotable
Market cap (USD): 11,934,667,326Global Median: 1,180,223,658.953
Revenue is $1.28B, above the global median of $548.88MNotable
Revenue (USD): 1,283,939,968Global Median: 548,883,780.48
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang NHU Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Swedish Orphan Biovitrum AB
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cipla Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Biomarin Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Recordati Industria Chimica e Farmaceutica S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CSPC Pharmaceutical Group Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Laurus Labs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Haisco Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Summit Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Corcept Therapeutics Incorporated
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Surrozen, Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
JFrog Ltd.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Fastly Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC